MXPA00013019A - Ciclosporina novedosa con perfil de actividad mejorado. - Google Patents
Ciclosporina novedosa con perfil de actividad mejorado.Info
- Publication number
- MXPA00013019A MXPA00013019A MXPA00013019A MXPA00013019A MXPA00013019A MX PA00013019 A MXPA00013019 A MX PA00013019A MX PA00013019 A MXPA00013019 A MX PA00013019A MX PA00013019 A MXPA00013019 A MX PA00013019A MX PA00013019 A MXPA00013019 A MX PA00013019A
- Authority
- MX
- Mexico
- Prior art keywords
- meleu
- val
- ala
- cyclosporin
- solution
- Prior art date
Links
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 54
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 53
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 53
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 47
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 25
- 230000000694 effects Effects 0.000 title description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- QHRMEJWWMGUKAM-LURJTMIESA-N (2s)-2-(ethylazaniumyl)-3-methylbutanoate Chemical compound CCN[C@@H](C(C)C)C(O)=O QHRMEJWWMGUKAM-LURJTMIESA-N 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000001506 immunosuppresive effect Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 102000004631 Calcineurin Human genes 0.000 description 5
- 108010042955 Calcineurin Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010036941 Cyclosporins Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010072220 Cyclophilin A Proteins 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 101150098622 gag gene Proteins 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000222519 Agaricus bisporus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 description 1
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 description 1
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 description 1
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 description 1
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Natural products C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 for example Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH140598 | 1998-07-01 | ||
| PCT/IB1999/001232 WO2000001715A1 (fr) | 1998-07-01 | 1999-06-30 | Nouvelle cyclosporine ayant un profil d'activite ameliore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA00013019A true MXPA00013019A (es) | 2003-07-14 |
Family
ID=4209677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA00013019A MXPA00013019A (es) | 1998-07-01 | 1999-06-30 | Ciclosporina novedosa con perfil de actividad mejorado. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | USRE40987E1 (https=) |
| EP (1) | EP1091975B1 (https=) |
| JP (1) | JP4350898B2 (https=) |
| CN (1) | CN1218958C (https=) |
| AT (1) | ATE312843T1 (https=) |
| AU (1) | AU759480B2 (https=) |
| BR (1) | BR9911724A (https=) |
| CA (1) | CA2335903C (https=) |
| DE (1) | DE69928938T2 (https=) |
| DK (1) | DK1091975T3 (https=) |
| ES (1) | ES2255275T3 (https=) |
| MX (1) | MXPA00013019A (https=) |
| PT (1) | PT1091975E (https=) |
| WO (1) | WO2000001715A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1091975E (pt) | 1998-07-01 | 2006-05-31 | Debiopharm Sa | Nova ciclosporina com um perfil de actividade melhorado |
| US6790935B1 (en) | 1999-02-05 | 2004-09-14 | Debiopharm S.A. | Cyclosporin derivatives and method for the production of said derivatives |
| CN1507451A (zh) | 2001-04-20 | 2004-06-23 | �±Ȱ·�ķ�ɷ�����˾ | 可用作前体药物的修饰环孢菌素及其应用 |
| EP1603512A2 (en) * | 2003-03-17 | 2005-12-14 | Albany Molecular Research, Inc. | Novel cyclosporins |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| US20060035821A1 (en) * | 2004-08-16 | 2006-02-16 | Hunt Kevin W | Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US7378391B2 (en) | 2004-09-29 | 2008-05-27 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| US7196161B2 (en) | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| KR101309409B1 (ko) * | 2004-10-01 | 2013-09-23 | 싸이넥시스, 인크. | Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체 |
| BRPI0515494A (pt) | 2004-10-01 | 2008-07-29 | Debiopharm Sa | uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| PT1853296E (pt) * | 2005-01-10 | 2012-09-26 | Debiopharm Sa | Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica |
| KR20080059270A (ko) | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 |
| DE602006020152D1 (de) | 2005-09-30 | 2011-03-31 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| KR101273681B1 (ko) | 2005-10-26 | 2013-06-25 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 시클릭 펩티드 화합물 |
| US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| DK2023918T3 (da) | 2006-05-19 | 2011-04-26 | Scynexis Inc | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser |
| JP2009539292A (ja) * | 2006-06-02 | 2009-11-12 | ぺリション、クロード、アニー | 活性電子の管理 |
| CN101108178B (zh) * | 2006-07-20 | 2010-09-15 | 复旦大学 | 一种亲环素a抑制剂在制备抗艾滋病药物中的应用 |
| KR20090083902A (ko) * | 2006-10-12 | 2009-08-04 | 노파르티스 아게 | 개질된 사이클로스포린의 용도 |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| CA2674296C (en) * | 2007-01-04 | 2015-11-24 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| AU2008250254B2 (en) | 2007-05-02 | 2012-08-16 | Astellas Pharma Inc. | New cyclic peptide compounds |
| US8394763B2 (en) | 2007-09-26 | 2013-03-12 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| WO2009098533A1 (en) * | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| WO2009148615A1 (en) * | 2008-06-06 | 2009-12-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
| JP5820722B2 (ja) * | 2008-06-06 | 2015-11-24 | スシネキス インク | シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用 |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| US8536114B2 (en) * | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
| WO2010088573A1 (en) * | 2009-01-30 | 2010-08-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c infection |
| US8685917B2 (en) * | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| AU2010333656B2 (en) * | 2009-12-18 | 2015-08-27 | Boehringer Ingelheim International Gmbh | HCV combination therapy |
| JP5947724B2 (ja) | 2009-12-21 | 2016-07-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | シクロフィリンの新しいインヒビター及びその使用 |
| WO2012009715A2 (en) | 2010-07-16 | 2012-01-19 | S&T Global Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| US20130267460A1 (en) * | 2010-09-16 | 2013-10-10 | The Johns Hopkins University | Methods of Inhibiting Alphavirus Replication and Treating Alphavirus Infection |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| WO2012079172A1 (en) | 2010-12-15 | 2012-06-21 | Isotechnika Pharma Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE112012002748T5 (de) | 2011-10-21 | 2014-07-31 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SE1450131A1 (sv) | 2011-10-21 | 2014-05-07 | Abbvie Inc | DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV |
| AR090964A1 (es) * | 2012-05-09 | 2014-12-17 | Novartis Ag | Proceso para la elaboracion de undecapeptidos ciclicos |
| EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
| WO2014085623A1 (en) | 2012-11-28 | 2014-06-05 | Enanta Pharmaceuticals, Inc. | Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues |
| WO2015031381A1 (en) | 2013-08-26 | 2015-03-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c |
| CN104744570A (zh) * | 2013-12-31 | 2015-07-01 | 深圳先进技术研究院 | 一种环孢菌素的合成方法 |
| US9669095B2 (en) | 2014-11-03 | 2017-06-06 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US20230149504A1 (en) | 2020-04-06 | 2023-05-18 | Debiopharm International Sa | Alisporivir for use in human viral infections |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH614931A5 (https=) | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
| US4210581A (en) | 1975-11-04 | 1980-07-01 | Sandoz Ltd. | Organic compounds |
| DE2819094A1 (de) | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
| SE448386B (sv) | 1978-10-18 | 1987-02-16 | Sandoz Ag | Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem |
| EP0034567B1 (en) | 1980-02-14 | 1984-11-07 | Sandoz Ag | A method for the total synthesis of cyclosporins and novel cyclosporins |
| US4396542A (en) | 1980-02-14 | 1983-08-02 | Sandoz Ltd. | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
| DE3047662C2 (de) | 1980-12-18 | 1985-02-21 | Karl M. Reich Maschinenfabrik GmbH, 7440 Nürtingen | Puffersystem bei Einschlaggeräten |
| DE3260468D1 (en) | 1981-01-09 | 1984-09-06 | Sandoz Ag | Novel cyclosporins |
| US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| ATE92501T1 (de) | 1984-10-04 | 1993-08-15 | Sandoz Ag | Monoklonale antikoerper gegen zyklosporine. |
| EP0194972B1 (en) | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US4814323A (en) | 1986-03-25 | 1989-03-21 | Andrieu J M | Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus |
| ES2059558T3 (es) | 1987-06-17 | 1994-11-16 | Sandoz Ag | Ciclosporins y su uso como productos farmaceuticos. |
| GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| DE69124459T3 (de) | 1990-11-02 | 2001-05-31 | Novartis Ag, Basel | Zyklosporine |
| ATE209216T1 (de) * | 1995-07-17 | 2001-12-15 | Chem Ag C | Cyclosporin-derivate mit anti-hiv-wirkung |
| JP3089350B2 (ja) | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | シクロフィリンロタマーゼ活性の阻害剤 |
| FR2757521B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| PT1091975E (pt) | 1998-07-01 | 2006-05-31 | Debiopharm Sa | Nova ciclosporina com um perfil de actividade melhorado |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| US7439277B2 (en) | 2005-05-19 | 2008-10-21 | Fina Technology, Inc. | In-situ preparation of hydroperoxide functionalized rubber |
-
1999
- 1999-06-30 PT PT99926684T patent/PT1091975E/pt unknown
- 1999-06-30 ES ES99926684T patent/ES2255275T3/es not_active Expired - Lifetime
- 1999-06-30 US US12/123,601 patent/USRE40987E1/en not_active Expired - Lifetime
- 1999-06-30 US US09/720,923 patent/US6927208B1/en not_active Ceased
- 1999-06-30 DE DE69928938T patent/DE69928938T2/de not_active Expired - Lifetime
- 1999-06-30 BR BR9911724-0A patent/BR9911724A/pt not_active Application Discontinuation
- 1999-06-30 MX MXPA00013019A patent/MXPA00013019A/es active IP Right Grant
- 1999-06-30 CN CNB998081558A patent/CN1218958C/zh not_active Expired - Lifetime
- 1999-06-30 WO PCT/IB1999/001232 patent/WO2000001715A1/fr not_active Ceased
- 1999-06-30 EP EP99926684A patent/EP1091975B1/fr not_active Expired - Lifetime
- 1999-06-30 CA CA002335903A patent/CA2335903C/fr not_active Expired - Lifetime
- 1999-06-30 AT AT99926684T patent/ATE312843T1/de active
- 1999-06-30 JP JP2000558116A patent/JP4350898B2/ja not_active Expired - Lifetime
- 1999-06-30 AU AU43856/99A patent/AU759480B2/en not_active Expired
- 1999-06-30 DK DK99926684T patent/DK1091975T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| DK1091975T3 (da) | 2006-04-18 |
| EP1091975B1 (fr) | 2005-12-14 |
| ATE312843T1 (de) | 2005-12-15 |
| DE69928938D1 (de) | 2006-01-19 |
| CA2335903A1 (fr) | 2000-01-13 |
| CA2335903C (fr) | 2009-11-10 |
| EP1091975A1 (fr) | 2001-04-18 |
| CN1308635A (zh) | 2001-08-15 |
| JP2002519434A (ja) | 2002-07-02 |
| DE69928938T2 (de) | 2006-08-17 |
| CN1218958C (zh) | 2005-09-14 |
| US6927208B1 (en) | 2005-08-09 |
| AU4385699A (en) | 2000-01-24 |
| AU759480B2 (en) | 2003-04-17 |
| ES2255275T3 (es) | 2006-06-16 |
| BR9911724A (pt) | 2001-03-20 |
| PT1091975E (pt) | 2006-05-31 |
| WO2000001715A1 (fr) | 2000-01-13 |
| JP4350898B2 (ja) | 2009-10-21 |
| USRE40987E1 (en) | 2009-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU759480B2 (en) | Novel cyclosporin with improved activity profile | |
| FI111730B (fi) | Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi | |
| JP5307169B2 (ja) | ＣＸＣＲ４拮抗活性を有するテンプレート固定βヘアピンペプチド擬似体 | |
| US6316405B1 (en) | Cyclosporin a conjugates and uses therefor | |
| CA2036963A1 (en) | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 | |
| US20040235716A1 (en) | Novel cyclosporins | |
| KR101443171B1 (ko) | 프로테아제 저해 활성을 가지는 주형-고정된 β-헤어핀 구조의 펩티드모방체 | |
| RU2085589C1 (ru) | Циклоспорины | |
| RO110144B1 (ro) | Noi ciclosporine, procedeu de sinteză a acestora și metodă de tratament și prevenire a SIDA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |